Owen Claire M, Asopa Sanjay, Smart Neil A, King Nicola
School of Biomedical Sciences, Faculty of Health, University of Plymouth, Plymouth, UK.
South West Cardiothoracic Centre, University Hospitals Plymouth, Plymouth, UK.
J Card Surg. 2020 Oct;35(10):2737-2746. doi: 10.1111/jocs.14895. Epub 2020 Aug 16.
Consensus on the optimum choice of cardioplegia remains elusive. One possibility that has been suggested to have beneficial properties is microplegia, a cardioplegia of reduced crystalloid volume. The aim of this meta-analysis is to comprehensively investigate microplegia against a range of clinical outcomes.
To identify potential studies, systematic searches were carried out in four databases (eg, Pubmed, EMBASE). The search strategy included the key concepts of "microplegia" OR "mini-cardioplegia" OR "miniplegia" AND "cardiac surgery." This was followed by a meta-analysis investigating: mortality, crystalloid volume; cardiopulmonary bypass time; cross-clamp time; intra-aortic balloon pump use; spontaneous heartbeat recovery; inotropic support; low cardiac output syndrome; myocardial infarction; acute renal failure; atrial fibrillation, reoperation for bleeding; creatine kinase myocardial band (CK-MB); intensive care unit (ICU) time and hospital stay.
Eleven studies comprising 5798 participants were analyzed. Microplegia used a lower volume of crystalloids and led to a higher spontaneous return of heartbeat, odds ratio (OR) 4.271 (95% confidence intervals [CIs]: 1.935, 9.423; I = 76.57%; P < .001) and a lower requirement for inotropic support, OR: 0.665 (95% CI: 0.47, 0.941; I = 3.53%; P = .021). Microplegia was also associated with a lower CK-MB release, mean difference (MD) -6.448 ng/mL (95% CI: -9.386, -3.511; I = 0%; P < .001) and a shorter ICU stay, MD: -0.411 days (95% CI: -0.812, -0.009; I = 17.65%; P = .045). All other comparisons were nonsignificant.
Microplegia has similar effects to other types of cardioplegia and is beneficial with regard to spontaneous return of heartbeat, inotropic support, ICU stay, and CK-MB release.
关于心脏停搏液的最佳选择仍未达成共识。一种被认为具有有益特性的可能性是微停搏液,即晶体液体积减少的心脏停搏液。本荟萃分析的目的是全面研究微停搏液对一系列临床结局的影响。
为了识别潜在的研究,在四个数据库(如PubMed、EMBASE)中进行了系统检索。检索策略包括“微停搏液”或“迷你心脏停搏液”或“微停搏”以及“心脏手术”的关键概念。随后进行了一项荟萃分析,研究内容包括:死亡率、晶体液体积;体外循环时间;主动脉阻断时间;主动脉内球囊泵的使用;自主心跳恢复;血管活性药物支持;低心排血量综合征;心肌梗死;急性肾衰竭;心房颤动、再次手术止血;肌酸激酶心肌型同工酶(CK-MB);重症监护病房(ICU)时间和住院时间。
分析了11项研究,共5798名参与者。微停搏液使用的晶体液体积较少,导致自主心跳恢复率更高,比值比(OR)为4.271(95%置信区间[CI]:1.935,9.423;I² = 76.57%;P <.001),血管活性药物支持需求更低,OR为:0.665(95% CI:0.47,0.941;I² = 3.53%;P = 0.021)。微停搏液还与较低的CK-MB释放相关,平均差异(MD)为-6.448 ng/mL(95% CI:-9.386,-3.511;I² = 0%;P <.001)以及较短的ICU住院时间相关,MD为-0.411天(95% CI:-0.812,-0.009;I² = 17.65%;P = 0.045)。所有其他比较均无统计学意义。
微停搏液与其他类型的心脏停搏液具有相似的效果,在自主心跳恢复、血管活性药物支持、ICU住院时间和CK-MB释放方面具有益处。